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Introduction: Mesenchymal stem cells (MSCs) are a multipotent population of adult stem cells, which may
represent a promising therapeutic approach for neurological autoimmune diseases such as multiple sclerosis. The
mouse is the most used species for obtaining and studying the characteristics of MSC and their potential as
autologous transplants in pre-clinical models. However, conflicting data have been published disclosing intraspecies
variations. The choice of the mouse strain and the tissue source appear, among others, as important factors in the
experimental application of MSCs.
Methods: Adipose tissue-derived MSCs obtained from the SJL/JCrl mouse strain (SJL-AdMSC) have been cultured for a
long time (from passage 0 up to 15) under controlled experimental conditions, and their growth rate, morphology,
stromal and haematopoietic marker expression profiles and differentiation capacity towards adipocytes, osteocytes and
chondrocytes have been determined. Moreover, their preclinical efficacy has been assessed by autologous transplant in
relapsing-remitting experimental autoimmune encephalomielitis (RR-EAE)-induced SJL mice (a well established mice
model for the study of RR-multiple sclerosis).
Results: We demonstrate that SJL-AdMSCs show the same fibroblastic shape, growth rate, profile of markers expression
and multipotency described for MSCs in every passage evaluated (up to passage 15). Additionally, SJL-AdMSCs ameliorate
the RR-EAE course, suggesting that they could modulate disease progression. Moreover, their features studied are fully
comparable with the standardized Ad-MSCs obtained from the C57BL/6 mouse strain, which strengthens their use in
cell therapy.
Conclusion: SJL-AdMSCs might be a suitable source of Ad-MSCs for studies related to the properties of MSCs and their
application as promising therapeutic tools in autologous transplants in experimental medicine.Introduction
Mesenchymal stem cells (MSCs) are a multipotent and
heterogeneous subset of adult stromal stem cells present
in many tissues. Traditionally, the study of the thera-
peutic potential of these cells has been oriented to their
application in tissue repair and regeneration, due to their
differentiation capacity and transdifferentiation into dif-
ferent cell lines [1,2]. However, over the past decade,* Correspondence: marga.suardiaz@gmail.com
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article, unless otherwise stated.MSCs have been shown to possess a broad spectrum of
immunoregulatory capabilities affecting both adaptive
and innate immunity. This has been proven by in vitro
experiments and their effectiveness when transplanted
into animal models of autoimmune diseases [3-5]. MSCs
therefore represent a promising tool as cell therapy, not
only for regenerative medicine but also for modulation
of the immune system [6-9].
The biological characteristics with which cell popula-
tions must comply to be defined as MSCs are clear, re-
gardless of the tissue of origin [10,11]. In recent years,
several studies have described isolation protocols, culture,
expansion, phenotypic and functional characterization of
human and animal MSCs derived from different tissuesCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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similar, contradictory results have been obtained revealing
interspecies/intraspecies variations regarding cell morph-
ology, cell survival and senescence [18], cell proliferation,
surface marker profile, growth kinetics [9,12,15], differen-
tiation capacity [3,16], gene expression [13], genetic in-
stability or even malignant transformation [14], among
others. All these conflicting data may be a result of a
multitude of factors that have been shown to play an im-
portant role in these biological characteristics, such as cell
isolation protocols, culture medium formulation [9,15],
cell density of the starting culture [17], different culture
time and expansion conditions [9,14,15], species and/or tis-
sue source from which MSCs are obtained [12,13,15,19-21]
and experimental approaches [15,16,19,22], which vary
among researchers. It is currently hard to compare the
results from different laboratories, which highlights the
necessity to define the best isolation site and expansion
methods for MSCs.
The ultimate goal in MSC research is to treat human
patients at the clinic with their own MSCs, since autolo-
gous transplantation provides two main theoretical ad-
vantages: a minimization of the risk of transmission of
infectious diseases and an increased efficiency in the ab-
sence of rejection by the patient’s immune system [23].
The only way to truly imitate this strategy in animal
studies is by transplanting animals with MSCs derived
from a peer animal of the same species and strain [24].
The mouse is a very suitable experimental system to
study MSC biology and their potential clinical benefits.
Although several reports have been published comparing
MSCs from different mice strains and tissues, there is
currently no consensus in the culture conditions nor in
the description of the disagreements existing between
these cells [12-15,19-21]. These features limit greatly
the ability to test the cells in the large number of inter-
esting murine models now available for autoimmune
and neurodegenerative diseases and/or for transgenic
mice, in which the mouse genetic background largely
influences the experimental model [25-27]. In this
sense, the choice of the mouse strain and the tissue
source appear as important factors in the experimental
application of MSCs.
Here we have made a comparative characterization,
under the same experimental conditions, of adipose
tissue-derived mesenchymal stem cells (Ad-MSCs) from
two different mouse inbred strains, C57BL/6 and SJL/
JCrl. C57BL/6 is one of the most used mouse strains in
basic and preclinical research, and represents a general
multipurpose model, which is also frequently used in
diet-induced obesity studies, transgenic/knockout model
development and safety and efficacy drug testing, among
others. The SJL/JCrl mouse strain is less common but
not the least, being especially important in studies focusedon retinal degeneration [28] and also for developing trans-
genic models [29].
Furthermore, both C57BL/6 and SJL/JCrl strains provide
a useful experimental tool, since they both carry the sus-
ceptible genetic backgrounds more commonly used to de-
velop experimental autoimmune encephalomyelitis (EAE)
in mice. EAE is an animal model of T-cell-mediated cen-
tral nervous system demyelination and represents the
most frequently used animal model for multiple sclerosis
(MS) research. MS has several clinical forms, including
initial attacks of optic neuritis, episodes of relapsing and
remitting paralysis and sensory deficits, and more pro-
gressive deteriorations [30]. Although there is not a sin-
gle animal model that can capture the entire spectrum
of heterogeneity of human MS and its variety in clinical
and radiological presentation, over the last decades use-
ful and relevant EAE animal models that share clinical
and neuropathological changes with human disease
have been developed [30-34]. Thereby, chronic pro-
gressive experimental autoimmune encephalomyelitis
(CP-EAE) models, in which neurological deficit ad-
vances in a progressive course or becomes chronic over
time without clear episodes of relapse and remission,
approach the model of the primary progressive form of
MS in humans. Otherwise, by mimicking the relaps-
ing–remitting MS progression form, the relapsing–re-
mitting experimental autoimmune encephalomyelitis
(RR-EAE) model facilitates the study of the underlying
mechanisms of relapses and remittances [30,35]. This
wide variety of clinical EAE courses is determined by
multiple factors used to induce the model, such as the
animal’s sex, the strain genetic background, the antigen
used for immunization, and so forth. Whereas the
C57BL/6 mouse strain is the most widely used to develop
myelin oligodendrocyte glycoprotein 35–55-induced
CP-EAE, the SJL/JCrl strain is usually preferred to set the
myelin proteolipid protein 139–151-induced RR-EAE
model [25,35-39].
Current MS cell-based therapeutics, as in many
other diseases, require validating in animal models,
replicating the possible pathological courses as well as
the characterization of many factors in order to ex-
clude possible variability sources in the results. The
Ad-MSC cultures obtained from the C57BL/6 mice
strain (C57-AdMSCs) had been characterized previously,
and based on their immunophenotype and growth poten-
tial they are considered a suitable source to establish a
mouse model for obtaining Ad-MSCs in preclinical stud-
ies [12,13,15,16]. Moreover, many preclinical works have
reported their immunomodulatory effects in EAE
models, which makes them a valuable tool for stem cell-
based therapy in immune-mediated diseases [4,5,40]. In
contrast, to the best of our knowledge, analogous studies
have not been performed with Ad-MSCs from the SJL/
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SJL-AdMSCs is therefore essential for preclinical studies
of autologous transplantations in this and other diseases.
In this study we demonstrate that, under our experi-
mental conditions, SJL-AdMSCs can be isolated, ex-
panded and maintained in culture for a long period of
time with a stable growth rate in a highly reproducible
manner. These cells also fulfill the characteristics that
define MSCs regarding morphology, immunophenotype
and differentiation capacity. In addition, we developed a
preclinical study showing that SJL-AdMSCs reduce dis-
ease severity in RR-EAE-SJL/J-induced mice. Our find-
ings therefore suggest that the SJL/JCrl mouse strain
may be an adequate source for obtaining Ad-MSCs for




All experiments were conducted using adult (6 to 8 weeks
old) female mice from SJL/JCrl (H2s) and C57BL/6 (H2b)
mouse inbred strains, purchased from Charles River
Laboratories International, Inc. (Barcelona, Spain). These
animals were housed in clear plastic cages under specific
pathogen-free conditions in accordance with institutional
guidelines. A controlled temperature (23 ± 1°C), a 12-hour:
12-hour light/dark cycle and free access to food and water
were set. The study was approved by the Ethics and
Research Committee of the Carlos Haya Regional
Hospital, and all experiments were performed in compli-
ance with the European Animal Research Laws (European
Communities Council Directives 2010/63/EU, 90/219/
EEC, Regulation (EC) No. 1946/2003) and the Spanish
National and Regional Guidelines for Animal Experi-
mentation and Use of Genetically Modified Organisms
(Real Decreto 53/2013 and 178/2004, Ley 32/2007 and
9/2003, Decreto 320/2010).
Isolation, culture and expansion of adipose-derived
mesenchymal stem cells
After sacrificing the mice by cervical dislocation, adipose
tissue fragments were obtained from subcutaneous ab-
dominal fat tissue. The isolation of murine Ad-MSCs from
both strains was performed attending to slight modifica-
tions from a previously described protocol [4]. Briefly, the
adipose tissue fragments were washed in Dulbecco's
modified Eagle's medium, mechanically dissociated and
subsequently digested in serum-free Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich Química S.L., Madrid, Spain)
supplemented with collagenase A (1 mg/ml; Worthington,
NJ, USA), gently shaking for 2 hours at 37°C. After tissue
disaggregation, the cellular suspension was filtered through
a 100 μm cell strainer (Becton Dickinson, Franklin Lakes,
NJ, USA) to remove debris and centrifuged twice to washthe cells. The resulting pellet was resuspended in a specific
growth medium for murine MSCs, Complete MesenCult®
Medium – that is, MesenCult® Basal Medium supple-
mented with MESENCULT® Mesenchymal Stem Cell
Stimulatory Supplements (both STEMCELLS Technolo-
gies, Grenoble, France) – streptomycin and penicillin
(PAA Laboratories GmbH, Pasching, Austria), and there-
after seeded in culture plates (1 × 106 cells per 9.6 cm2
dish) until the cell culture reached 100% confluence.
The Ad-MSCs were then trypsinized and expanded
in vitro with the aforementioned supplemented medium,
replacing it every 2 days during the expansion phase.
The cells were plated at 6 × 103 cells/cm2 in cell culture
dishes (450,000 cells per 75 cm2 dish) and cultured in a
37°C incubator with a 5% carbon dioxide atmosphere.
Every time they reached 80% confluence, the cells were
trypsinized, harvested and counted. The cells were then
subcultured at the same cell density from one up to 15
passages.
We performed four replicates for each inbred strain.
Each replicate was a mixture of Ad-MSCs obtained from
two mice.
Biological characteristics of the adipose tissue-derived
MSCs
Cell morphology was determined by direct visualization
with a trinocular inverted phase contrast microscope
(Leica DMIL LED; Leica Microsystems, Inc., Barcelona,
Spain). Images were captured at 10× magnification.
The population growth rate was calculated by deter-
mining the doubling time (period of time required to
double the size of the population) using the Schwartz
formula [41,42]:
DT ¼ t log2
3 logDt=Do
:
where DT is the cell population doubling time, t is the
time lapse between two measurements (two consecutive
culture passages), Dt is the number of cells at the final
measurement (in passage X + 1), and D0 is the number
of cells at the initial measurement (in passage X). During
the expansion phase, to calculate the DT, the number of
grown cells was obtained using the conventional Trypan
Blue vital stain methodology in all passages. Data are
expressed in hours, and are presented as the mean ±
standard error of the mean (SEM) of four DT values
obtained from Ad-MSC cultures of each strain.
Adipose tissue-derived MSC surface marker expression:
fluorescence-activated cell sorting analysis
For phenotyping, the cells harvested from each passage
(passages 3 to 15) were aliquoted (1 × 105 cells/vial), washed
with saline and stained using fluorescein isothiocyanate,
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nin orallophycocyanin–Cy7 mouse monoclonal antibodies
against mouse stromal markers CD44, CD106 (Becton
Dickinson) or CD90.2 (eBioscience, San Diego, CA, USA),
as appropriate, at 4°C for 30 minutes. In addition, the ab-
sence of hematopoietic markers was assessed by staining
cells with monoclonal antibodies against mouse CD45 (Mil-
tenyi Biotec S.L., Madrid, Spain), CD14 and CD34 (Becton
Dickinson). Isotype-matched antibodies were used as con-
trols. We also observed the cells’ size and granularity by
analyzing the forward-scatter signal and side-scatter signals
during the culture time. The forward scatter signal is
expressed in arbitrary units.
After being washed with phosphate-buffered saline,
the cells were fixed in phosphate-buffered saline with 1%
paraformaldehyde (PFA; Sigma-Aldrich Química S.L.,
Madrid, Spain). At least 5,000 events were collected for
further analysis using a FACSCanto II cytometer and
FACSDiva software (Becton Dickinson).
Summarized results are presented as arithmetic means ±
SEM of four samples from each strain per culture passage.
The Mann–Whitney U test was used to evaluate the dif-
ferences between the mouse strains within each passage.
P <0.05 was considered statistically significant.
Adipose tissue-derived MSC differentiation assays
The adipogenic, osteogenic and chondrogenic potential
was tested, in duplicate, in Ad-MSC populations from
both strains at passages 7 and 15, according to the follow-
ing protocols.
Briefly, Ad-MSCs were seeded at 6 × 104 cells per well
in a 24-well tissue culture plate (3 × 104 cells/cm2) using
Complete MesenCult® Medium. After they reached 80%
semiconfluence, induction was carried out by replacing
the growth medium for the supplemented MSC Adipo-
genic or Osteogenic Differentiation Medium (Ready-to-use)
(PromoCell GMBH, Heidelberg, Germany) as appropriate,
which contained all of the growth factors and supplements
necessary for an optimal differentiation, streptomycin and
penicillin. The media was carefully replaced every
2-3 days for 14 or 21 days, depending on whether it was
adipogenesis or osteogenesis. The acquisition of the adi-
pogenic phenotype was then confirmed by staining the
monolayers – previously fixed in 4% PFA, and preincu-
bated in 60% isopropanol – with a 0.25% Oil Red-O so-
lution (PromoCell GMBH) and counterstaining with
hematoxylin and eosin. The Ad-MSC colonies which
underwent adipogenic differentiation exhibited cells
that contained numerous, variable-sized lipid vesicles.
To observe osteogenic mineralization, the cultures were
prefixed in 4% PFA, washed once with phosphate-
buffered saline, and stained for 5 minutes at room
temperature with 2% Alizarin Red S stain (PromoCell
GMBH), pH 4.2, which stained cell calcium deposits.The excess stain was removed by several washes with
distilled water.
For chondrogenic differentiation, the Ad-MSCs were
plated at 1 × 105 cells per well in a 96-well U-bottom
suspension culture plate using Complete MesenCult®
Medium. Spheroids were spontaneously formed within
24 to 48 hours. After this period, the medium was re-
moved and the cells were incubated for 21 days with sup-
plemented MSC Chondrogenic Differentiation Medium
(PromoCell GMBH) containing streptomycin and penicil-
lin, carefully replaced every 2 to 3 days. The spheroids
were then fixed in 4% PFA, frozen and sectioned 25 mi-
crons thick in a freezing microtome. The sections were
stained with Alcian Blue 8GX (Sigma-Aldrich Química
S.L.) used to stain acidic polysaccharides such as glycos-
aminoglycans in cartilages and other body structures, and
counterstained with Nuclear Fast Red Solution (Sigma-
Aldrich Química S.L.).
All differentiation images were captured at 10× or 20×
magnification with a trinocular inverted phase contrast
microscope (Leica DMIL LED) to acquire adipocytes
and osteocytes images, and an Olympus BX41 Microscope
with the Olympus DP70 camera associated (Olympus
Iberia S.A.U., Barcelona, Spain) for chondrocyte images.
Experimental autoimmune encephalomyelitis induction
and clinical evaluation
CP-EAE was induced in C57Bl/6 (H2b) mice by subcutane-
ous immunization in the flanks with the myelin oligodendro-
cyte glycoprotein 35–55 (MEVGWYRSPFSRVVHLYRNGK)
peptide (200 μg; GenScript, Piscataway NJ, USA) emul-
sified in complete Freund’s adjuvant containing
0.8 mg/ml heat-inactivated Mycobacterium tubercu-
losis (Becton Dickinson) at a final volume of 100 μl.
The pertussis toxin (Sigma-Aldrich Química S.L.) was
administered intraperitoneally by injection at the dose
of 300 ng on days 0 and 2 post immunization.
To develop a RR-EAE, SJL/JCrl (H2s) mice were im-
munized using the same protocol described above but
by performing the emulsion with the proteolipid pro-
tein 139–151 (HSLGKWLGHPDKF) peptide (300 μg;
GenScript) as the antigen. Each animal also received a
total of 300 ng pertussis toxin through two intraperitoneal
injections on the immunization day and 48 hours later.
The clinical score was blindly registered according to a
standard 0 to 5 scale [43]: 0, healthy; 0.5, flaccidity and
partial paralysis of the tail; 1, limp tail; 1.5, weakness in
one hind limb; 2, hind limb paresis; 2.5, partial hind limb
paralysis; 3, total hind limb paralysis; 3.5, partial fore
limb paralysis; 4, hind limb paralysis and body/front
limb paresis/paralysis; and 5, moribund.
CP-EAE-induced animals were monitored over a 35-
day period and RR-EAE-induced animals over 50 days.
The endpoint evaluation included a variety of disease
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ity, the day of the disease onset, the maximal score, the
mean score reached in chronic phase in CP-EAE ani-
mals, the duration and the mean scores of the relapsing
periods in RR-EAE mice, and the cumulative score
over experimental times.
Treatment protocols
CP-EAE-induced and RR-EAE-induced animals from
both mouse strains were randomly distributed in groups
of 10 or 11 individuals to receive a unique administra-
tion of Ad-MSCs obtained from animals of their same
strain (autologous transplant). All of the experiments
were performed using Ad-MSCs at seven to 10 passages.
Cells were injected intravenously through the vein of the
tail when animals reached a clinical score between 0.5
and 1 (at 13 days post immunization (dpi) and 12 dpi
for CP-EAE and RR-EAE models, respectively). For each
injection, 1 × 106 Ad-MSCs were resuspended in 400 μl
saline as vehicle. The EAE-control mice group (n = 10 or
11) from both models received only vehicle (400 μl saline)
by a similar protocol.
Immunohistochemistry
EAE-induced animals were sacrificed by intraperitoneal
administration of a lethal dose of pentobarbital. Fresh
spinal cord extraction was performed at the chronifica-
tion period (35 dpi) in CP-EAE-induced animals and at
the peak of the second relapse (45 dpi) in RR-EAE mice.
The lumbar spinal zones were placed in 4% PFA
(Sigma-Aldrich Química S.L.), cryoprotected in 30% (w/v)
sucrose and cut in 40 μm cryostat sections. Histopatho-
logical analysis of spinal T-cell infiltrates and demyelin-
ation were determined by free-floating immunostaining
using antibodies against the CD3 antigen (rabbit poly-
clonal; Abcam plc, Cambridge, UK) and the myelin basic
protein antigen (rat monoclonal; Abcam plc), respectively.
For their detection, Extravidin® peroxidase (Sigma-Aldrich
Química, S.L.) and 3,3′-diaminobenzidine (Sigma-Aldrich
Química, S.L.) methods were used as described previ-
ously [44].
Analysis were carried out over 4× and 10× images
(three or four images per animal) using the microscope
described above. Inflammatory infiltrates were determined
by counting the number of labeled cells in 200 μm2. The
area of demyelination, in which staining was negative for
myelin basic protein, was expressed as the percentage of
total myelinated area per section. Data are shown as the
mean ± SEM of values obtained from six animals per ex-
perimental group.
Statistical analysis
The data were expressed as the mean ± SEM and were ana-
lyzed with SigmaStat (SPSS Inc.,IBM Corporation, NewYork, USA). Student’s t test or the Mann–Whitney U test
was used to compare pairs of groups from the different
mice and cell cultures studied. Minimal statistical signifi-
cance was set at P <0.05.
Results
Morphology and cell expansion characteristics of the
adipose tissue-derived MSCs
Ad-MSCs isolated from the SJL/JCrl mice strain (SJL-
AdMSCs) and from the C57BL/6 mice strain (C57-AdMSCs)
were seeded under the same conditions in culture plates and
expanded during 15 passages, displaying a similar volume and
cell morphology. The primary cultures (passage 0) of Ad-
MSCs contained heterogeneous cell populations with differ-
ent shapes. In this early phase, most of the cells were plastic
adherent. They showed a rounded morphology and grew
forming colonies, with no significant differences between the
cells from both strains (Figure 1). However, in the following
passages (from passages 1 to 15), where cells were seeded at a
lower density than in primary cultures, the Ad-MSCs showed
a fibroblastic-like shape and grew uniformly until confluence
by colonizing the entire plastic surface, regardless of the
mouse strain or culture passage analyzed (Figure 1).
To determine the potential growth rate of Ad-MSCs,
we calculated the time (in hours) that the population
took to double its number (DT) using the Schwartz for-
mula [42]. In general, the average of the growth rate of
Ad-MSCs increased gradually over the passages in both
C57-AdMSC and SJL-AdMSC populations, as demon-
strated by a decrease in the DT during cultivation (Table 1).
Passages in which the DT stabilized at its minimum values
were from 6 (15.5 ± 1.7) to 15 (16.5 ± 2.9) hours for the
C57-AdMSC population, and from 7 (21.9 ± 2.8) to 15
(19.8 ± 3.4) hours for SJL-AdMSCs.
Adipose tissue-derived MSC phenotype characteristics
Cells isolated from both mouse strains were analyzed in
each culture passage by flow cytometry for their pheno-
typic profile, previously reported to be determinative for
the MSCs [10]. Results showed that SJL-AdMSCs prolif-
erated to clearly homogeneous populations exhibiting a
forward scatter/side scatter signal plot of the median sig-
nal in the culture passages analyzed, which was attrib-
uted to the maintenance of the cell size (Figure 2) and
granularity (data not shown) during in vitro cultivation.
No differences were found after performing a t-test analysis
comparing them with the C57-AdMSC population.
Less than 10% of the SJL-AdMSCs expressed the
hematopoietic markers CD34, CD45 and CD14 in all of
the passages tested (Figure 3). On the other hand, SJL-
AdMSCs expressed variable levels of CD106 (VCAM-1),
CD90.2 (Thy-1.2) and CD44 (receptor for hyaluronate
and osteopontin) markers, with no statistically significant
differences when compared with the C57-AdMSC
Figure 1 Morphology of adipose tissue-derived mesenchymal stem cells isolated from SJL/JCrl and C57BL/6 mice strains. Images of the
C57-AdMSC and SJL-AdMSC cultures showing the morphology of the populations. Passage 0 (P0) images show cells with rounded morphology
and colony growth. Images from passages 1 (P1) to 15 (P15) show that plastic-adherent C57-AdMSCs and SJL-AdMSCs have a fibroblastic
morphology and expand primarily over the surface of culture dishes (original magnification 10×). Ad-MSC, adipose tissue-derived
mesenchymal stem cell.
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centage of Ad-MSCs expressing the CD106 marker
remained practically stable along the culture period with
no significant differences, in agreement with the homo-
geneity exhibited in both cell populations. Regarding the
CD44 and CD90 markers, the expression in the SJL-
AdMSC population was high and remained stable in time
through all of the passages. In C57-AdMSCs, this expres-
sion profile was similar, and kept until the end of the cul-
ture time.
Adipose tissue-derived MSC differentiation potential
To validate the multipotentiality of the SJL-AdMSCs
cultures, in vitro differentiation was induced into adipo-
genic, osteogenic and chondrogenic lineages in the mid-
dle and final phases of our experimental study (that is,
passages 7 and 15), being the culture passages among
those in which the cell growth rate stabilized at the max-
imum values.
For adipogenic differentiation, Ad-MSCs were cultured
in appropriate media for 16 days. The adipogenic poten-
tial of SJL-AdMSCs was similar in every passage evalu-
ated, and showed no differences when compared with
that of the C57-AdMSCs. After adipogenic induction, allof the Ad-MSC lines showed a high percentage of round
cells with lipid vesicles occupying the cytoplasm, which
is consistent with the phenotype of mature adipocytes
(Figure 4A). No lipid droplets were observed in undiffer-
entiated Ad-MSCs (control) in both passages analyzed.
SJL-AdMSC differentiation to osteocytes was evaluated
by incubating cells with a specific osteogenic differenti-
ation medium after 21 days. During this cultivation
period, multiple layers of cells were formed. In a high
percentage of the cases, these cells led to dense nodules
from which radiated highly elongated spindle-shaped
cells. Calcium deposition was demonstrated by Alizarin
Red staining (Figure 4B). In both passages tested, SJL-
AdMSCs and C57-AdMSCs showed a similar osteogenic
potential, with no differences between passages.
The SJL-AdMSCs that underwent in vitro chondrogenic
differentiation proliferated rapidly and formed spheroids
that increased in size over the course of the 3-week cul-
ture, being visible to the naked eye as early as day 3 after
chondrogenic induction. The differentiated cells were
positively stained by Alcian blue, specific for the glycosami-
noglycans in cartilage matrix. The Ad-MSCs from both SJL
and C57 strains showed similar potentials to differentiate to
chondrocytes at passages 7 and 15 (Figure 4C). Differences
Table 1 Doubling times of the adipose tissue-derived
mesenchymal stem cell populations
Passage C57 SJL
1 44.7 ± 15.5 82.9 ± 16.24
2 60.2 ± 20.3 86.3 ± 43.70
3 69.6 ± 5.6 52.1 ± 20.4
4 64.8 ± 40.7 37.5 ± 1.2
5 39.0 ± 5.45 35.8 ± 5.8
6 15.5 ± 1.7 26.8 ± 4.6
7 22.5 ± 3.1 21.9 ± 2.81
8 25.4 ± 3.4 20.7 ± 1.39
9 27.9 ± 6.6 20.4 ± 1.95
10 26.9 ± 5.3 27.1 ± 1.96
11 15.4 ± 5.7 24.0 ± 2.9
12 16.1 ± 5.8 22.1 ± 3.2
13 14.7 ± 1.2 17.8 ± 1.9
14 18.6 ± 6.7 14.3 ± 0.5
15 16.5 ± 2.9 19.8 ± 3.4
Comparison of the growth potential between the C57-AdMSC (C57) and SJL-AdMSC
(SJL) populations at passages 1 to 15. Population doubling times were calculated
using the Schwartz formula (see text). Table shows the mean ± standard error of the
mean of population doubling time values (in hours) obtained from the adipose
tissue-derived mesenchymal stem cell (Ad-MSC) cultures of three replicate plates of
each inbred mouse strain per passage.
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differentiation of the C57-AdMSC population in any of its
passages, demonstrating, as previously, the bona fide mul-
tipotent mesenchymal nature of the isolated SJL-AdMSCs.
Clinical and neuropathological effects of adipose
tissue-derived MSC therapy
The results showed that CP-EAE was developed in
C57Bl/6-EAE-induced mice with a 90% of the diseaseFigure 2 Characterization of cell size through successive
passages of the adipose tissue-derived mesenchymal stem cell
populations. Data represent the mean ± standard error of the mean
of the forward-scatter signal (FSC, arbitrary units) values obtained
from the adipose tissue-derived mesenchymal stem cell (Ad-MSC)
cultures of four replicate plates of each inbred mouse strain per
passage by flow cytometry.incidence (Figure 5A). The first clinical signs of EAE
appeared at 11.1 ± 0.2 dpi (mean ± SEM). Control mice,
treated intravenously with saline at 13 dpi, suffered in-
creased neurological deficit over time, and later pre-
sented a stable disease course, typical of this chronic
model. Mice treated with C57-AdMSCs at the same
time, showed a decrease in the severity of the disease,
as reflected in the drastic reduction of the mean max-
imum (1.9 ± 0.1 vs. 2.4 ± 0.1 in control mice; P <0.01)
and cumulative scores (31.6 ± 2.6 vs. 41.4 ± 2.0 in con-
trol mice; P <0.01) through the disease course. Further-
more, in these mice the chronic phase was established
with a moderate symptomatology, the mean clinical
score being significantly reduced when compared with
control animals (1.4 ± 0.1 vs. 2.0 ± 0.1; P <0.0001) over
this phase.
The MS RR-EAE model used in this study is charac-
terized by a relapsing–remitting type of neurological def-
icit. The clinical course of this model is characterized by
the appearance of at least two relapses separated by a
period of symptomatic remission (Figure 5B). The onset
of each relapse was considered when animals had a clin-
ical score of 1.5 or higher, and the remission was regarded
as the period in which the animals had 1.4 or less. Most of
the SJL/JCrl immunized animals developed symptoms
with no significant differences at the day of the disease on-
set between the experimental groups (11.4 dpi). Saline-
treated mice showed a very aggressive multiphasic disease
progression, as reflected by the highest maximum and cu-
mulative mean scores. By contrast, RR-EAE animals that
received a unique dose of SJL-AdMSCs at 12 dpi, pre-
sented a moderate clinical course with a significantly
reduced maximum (2.4 ± 0.2 vs. 3.4 ± 0.3; P <0.01) and cu-
mulative (52.5 ± 4.4 vs. 67.2 ± 7.6; P <0.05) mean scores.
Moreover, the autologous transplants were able to reduce
not only the duration of the relapses but also the severity
of the neurological deficit suffered by the mice in these
periods. Whereas control mice experienced a first 15-day
relapse with a mean score of 2.3 ± 0.1, cell-treated animals
reached a mean value of 1.7 ± 0.1 (P <0.0001 vs. saline) in
a first relapse that only lasted 5 days. Although the second
relapse was less aggressive than the first, cell therapy in-
duced a significant decrease of both the aggressiveness
(1.6 ± 0.1 vs. 2.1 ± 0.1; P <0.01) and the duration (4 vs.
10 days) of this relapse period when compared with the
animals treated with saline.
Finally, we evaluated the correlation of observed clinical
score amelioration with a reduction of the neurohisto-
pathological damage. In order to do this, and according
to the EAE clinical course, spinal cord processing was
performed at chronification (35 dpi) and second relapse
(45 dpi), in CP-EAE and RR-EAE animals, respectively.
As expected, immunohistochemistry staining of spinal
cord sections from chronified EAE saline-treated mice
Figure 3 Expression of stromal and hematopoietic markers in the SJL-AdMSC and C57-AdMSC populations by flow cytometry. Graphs
show the average (mean) of each CD marker expression percentage value ± standard error of the mean at passages 3 to 15. The Mann–Whitney
U test was performed to compare the expression between cell cultures. No statistically significant differences were found between groups.
Ad-MSC, adipose tissue-derived mesenchymal stem cell.
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http://stemcellres.com/content/5/6/134(CP-EAE) showed a minor presence of cell infiltrates ac-
companied by a considerable percentage of demyelin-
ation. No differences were found in T-cell infiltration
between CP-EAE mice, irrespective the treatment re-
ceived (Figure 6A) (4.2 ± 1.0 vs. 3.2 ± 0.9). The effect of
the treatment, however, was very noticeable on the per-
centage of the total demyelinated area, assessed by mye-
lin basic protein expression (Figure 6B). The autologous
transplants of Ad-MSCs thus significantly inhibited the
demyelination in the white matter of the lumbar spinal
cord (61.7 ± 4.0 vs. 6.8 ± 2.5; P <0.0001 treatment vs.
saline).
Similarly, cell therapy-mediated improvement of the
EAE clinical course associates with neurohistopathologi-
cal changes in RR-EAE mice. Consistent with the clinical
data, a reduction of the number of CD3-positive cells in
RR-EAE-induced animals was detected when treated
with autologous cell therapy (Figure 6A), although no
statistical differences were found when compared with
animals treated with saline (19.2 ± 3.1 vs. 10.8 ± 2.7).
Autologous Ad-MSC treatment also reduced signifi-
cantly the percentage of demyelination in the white
matter area of the lumbar spinal cord (18.6 ± 2.1 vs.
4.9 ± 0.2; P <0.0001 vs. saline), regardless of its minor
incidence (Figure 6B).Discussion
Preclinical studies on MSCs, including Ad-MSCs, have
allowed the cells to be considered as cell-based thera-
peutic strategies in regenerative medicine and auto-
immune diseases. However, discrepancies reported from
different authors regarding many biological features of
stem cells must be solved before translating stem cell
knowledge into clinical setting. The most contradictory
results are due to different laboratory procedures and
protocols, such as the tissue for obtaining MSCs, isola-
tion methods and culture conditions, among others
[9,12-15,19-21]. Different researchers also employ differ-
ent animal species/strains whose genetic background
make them more suitable to be used as a specific disease
model, focusing their efforts on establishing MSC au-
tologous transplantations as beneficial therapies in these
diseases. The identification and characterization of any
possible variability factors intrinsic to the animal model
or cell source in cell-based approaches is mandatory in
order to rule out false-positive results and to validate
therapies. For all of these reasons, we thought it would
be useful to compare the Ad-MSCs derived from differ-
ent mice strains.
Specifically, we provide comparative data regarding
the characteristics of Ad-MSCs from two inbred strains
Figure 4 Adipose tissue-derived mesenchymal stem cell differentiation. (A) Adipocytes (original magnification, 20×), (B) osteocytes (original
magnification, 10×) and (C) chondrocytes (original magnification, 10×). Images show the SJL-AdMSC and C57-AdMSC populations at culture
passages 7 (P7) and 15 (P15). Cell cultures were maintained in the growth media (Control) and stimulated to differentiation (Diff.) by incubation
with the specific media.
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http://stemcellres.com/content/5/6/134of mice, SJL/JCrl and C57BL/6, commonly employed to
develop animal models for a variety of diseases
[25,28,35-37]. Our data represent a pooling of Ad-MSCs
from several animals of each strain, specially focused on
interstrain differences and not on intrastrain differences,
assuming from our own observations that the latter are
minimal.
The results showed that Ad-MSCs isolated from SJL/
JCrl mice (SJL-AdMSCs) displayed an analogous morph-
ology and volume to those of the extensively studied
Ad-MSCs isolated from C57BL/6 mice (C57-AdMSCs)
when cultured for a long period of time under our ex-
perimental conditions. These results are in accordance
with those explaining that MSCs are fibroblastoid-like
cells enriched to homogeneity during a long-term cul-
ture [13,45], persisting only with minimal alterations in
cell morphology (size and shape) [22,46].
The Ad-MSC growth rate increased through different
culture passages, reaching its higher values after passage
7 for SJL-AdMSCs and after passage 6 for the C57-
AdMSC population, and the growth stabilized at those
values up to passage 15. These data suggest that, as wellas the absence of morphological evidence of cell aging
(distended or irregular flat cell shapes and more circum-
scribed nuclei under phase contrast microscopy), neither
SJL-AdMSCs nor C57-AdMSCs undergo senescence
phenomena at the highest passages evaluated. Our re-
sults are in agreement with previous studies in which
they have maintained a prolonged in vitro expansion of
murine MSCs, postulating that these cells, given the ap-
propriate conditions, will remain and proliferate in cul-
ture without decreasing their growth rate [13,19,22].
However, although we find no evidence of senescence
or slowing of growth with time, we cannot exclude that
different experimental approaches could further influ-
ence their behavior. Previous works have thus reported
evidence of senescent features under specific circum-
stances – that is, enlarged and irregular cell shapes and
ultimately a stop of proliferation – demonstrating that
many relevant factors play an important role in MSC
expansion, such as different culture times and condi-
tions, the tissue source from which MSCs are obtained,
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Figure 6 Cell therapy effects in inflammatory infiltrates and demyelination in the spinal cord of experimental autoimmune encephalomyelitis
mice. Representative lumbar spinal cord sections from experimental autoimmune encephalomyelitis (EAE) mice, stained with anti-CD3 or anti-myelin
basic protein (anti-MBP) antibodies to detect inflammatory infiltrates (A) and the degree of demyelination (B) in both chronic progressive experimental
autoimmune encephalomyelitis (CP-EAE)-induced and relapsing–remitting experimental autoimmune encephalomyelitis (RR-EAE)-induced animals.
Magnification: (A) 10× and (B) 4×. Graphs show the mean ± standard error of the mean of the number of T cells stained with CD3 in 200 μm2 (A), or the
demyelinated area, characterized by a lack of MBP staining related to the total area (B), from three sections of six animals per each experimental group.
t test: ***P <0.0005 vs. saline. Ad-MSC, adipose tissue-derived mesenchymal stem cell; DPI, days post immunization.
(See figure on previous page.)
Figure 5 Clinical outcome of experimental autoimmune encephalomyelitis models. (A) Chronic progressive experimental autoimmune
encephalomyelitis (CP-EAE) and (B) relapsing–remitting experimental autoimmune encephalomyelitis (RR-EAE) mice treated with C57-AdMSCs
and SJL-AdMSCs, respectively. Graphs show the clinical score progression of each EAE model over the experimental period. Black arrows point to
the day at which the treatment started. In the tables, the values are presented as mean ± standard error of the mean. Statistical analysis to perform
single comparisons was carried out using Student’s t test. *P <0.05, **P <0.01, ***P <0.0001 vs. saline. aDay disease onset, first day on which animals
show any clinical symptoms (clinical score ≥0.5). bMean chronic phase score, mean EAE score from each experimental group over the chronic phase
in CP-model (from 20 to 35 dpi). cMean cumulative score, average of the accumulated EAE score from each mouse over the entire experiment
(until 35 dpi in CP-EAE and until 50 dpi in RR-EAE). d,fDuration of first/second relapse, days of the first/second relapse. The beginning of the relapse was
established when the animals had a clinical score of 1.5 or higher, and the end of that period arrived when the score recovered that value. e,gMean of
first/second relapse score, average of the EAE score from each mouse over the mentioned relapsing periods. Ad-MSC, adipose tissue-derived mesenchymal
stem cell; dpi, days post immunization.
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http://stemcellres.com/content/5/6/134The SJL-AdMSC phenotype profile exhibited the lack
of expression of hematopoietic markers in all of the
passages evaluated. This result was very similar to that
of C57-AdMSCs and is in agreement with those de-
scribed in MSCs studies [9,14,15]. A variable expression
level of stromal markers was detected in the SJL-AdMSC
population, with no differences when compared with C57-
AdMSCs. Hence, there is general consensus that the
broad range of expression levels of these markers in MSCs
is mainly attributed to the MSC tissue source, a specific
culture and the experimental conditions [5,7,13,15,17,18].
The multipotency of the SJL-AdMSC population at
passages 7 and 15 was evaluated by in vitro differenti-
ation into mesodermic origin cell lineages. We con-
ducted these assays at those passages to ensure that the
differentiation capacity was not lost at the highest pas-
sages. As we expected, SJL-AdMSCs were differentiated
into adipocytes, osteoblasts and chondrocytes in both
passages tested, with no differences when compared with
C57-AdMSCs, indicating again their MSC condition.
Finally, we wanted to determine whether SJL-AdMSCs
also exhibit the in vivo immunomodulatory properties
described for C57-AdMSCs when transplanted into ani-
mal models of autoimmune diseases, as EAE [4,40]. The
EAE model plays an important role as a first-line model
system in MS research. The EAE model is characterized
by central nervous system inflammation and demyelin-
ation, like MS. Because there is no single EAE model
that mimics the broad symptomatic variability in MS, we
performed the autologous cell therapy in two frequently
used EAE models in mice, RR-EAE and CP EAE, covering
the clinical courses that appear more frequently in MS pa-
tients. As mentioned above, C57BL/6 and SJL/JCrl mouse
strains are genetically susceptible and appropriate to de-
velop CP-EAE and RR-EAE, respectively [25,35-39].
The autologous transplants were carried out with
Ad-MSCs from passages 7 to 9, this being the smaller
range of passages in which, in addition to complying
with the requirements for consideration as multipotent
mesenchymal cells, the growth rate of these cell popu-
lations was optimal for obtaining the cell number re-
quired for in vivo administration. Moreover, the cell
administration in lower passages might also avoid the
chromosomal alterations described for Ad-MSCs after
multiple divisions [13,18].
Our results showed that the autologous administration
of murine C57-AdMSCs after CP-EAE onset successfully
ameliorated the severity of the disease. Clinical efficacy
was demonstrated by a decreasing mean maximum and
the cumulative disease score, as well as in a lowering of
the clinical score in which the disease becomes chronic
and stable. As expected, immunohistological staining of
lumbar spinal cords showed a reduction of spinal cord
inflammation as well as of demyelinated area after celltransplant. These results are consistent with others pub-
lished previously [4,40,43].
As far as we know, this is the first study that describes
the in vivo efficacy of SJL-AdMSCs when transplanted in
RR-EAE induced mice. Gerdoni and colleagues reported
the immunomodulatory properties of bone marrow
MSCs isolated from C57BL/6 mice into the SJL-RR-EAE
model [47]; however, no one has presented a description
of or the preclinical study of the autologous transplant-
ation of SJL-AdMSCs in the RR-EAE model that we
present here. Results showed that symptoms in both the
first and the second relapses lasted less time in trans-
planted animals than in those treated with saline, and
the mean score reached over these periods was signifi-
cantly reduced when compared with control mice. Cell
transplantation significantly reduced the maximum and
the cumulative score, inducing a less aggressive EAE in
animals. These findings corroborate the clinical efficacy
of Ad-MSC in EAE models.
Interestingly, neuropathological analysis confirmed that
clinical amelioration was accompanied by a reduction
of both central inflammation and demyelination in
SJL-AdMSCs treated animals in comparison with con-
trol mice. These results suggest that this therapy could
play an important role in counteracting the inflammatory
processes occurring during relapse periods, and in neu-
tralizing the neurodegeneration process, characteristic of
the long-term progression of this RR-EAE model [39].
It is important to note that CP-EAE and RR-EAE models
cannot be compared due to the various pathological pro-
cesses determined by the different clinical courses, as dem-
onstrated by significant differences in data concerning the
number of T cells infiltrated and the total demyelinated
area obtained from control animals. Notwithstanding, we
could establish that autologous Ad-MSC transplantation
is effective in modulating both models, possibly through
mechanisms mainly based on immunomodulation and
neuroprotection, as demonstrated in this work and by
others.
Conclusions
Our results demonstrate that isolated SJL-AdMSCs share
in vitro mesenchymal similarities with standardized C57-
AdMSCs, suggesting that the former might serve as an ex-
perimental model for many studies in the same way as the
latter. In our hands, Ad-MSC populations tested at differ-
ent culture passages, are appropriate for their experimen-
tal use, since cells fulfill the optimal morphology and
phenotypic profile of MSCs, showing the highest and most
stable growth rate, maintaining their multipotency and
presenting immunomodulatory effects.
Most importantly, our data suggest that the SJL/JCrl
mouse inbred strain might be a very suitable source of
Ad-MSCs (as well as C57BL/6 mice) for preclinical
Marin-Bañasco et al. Stem Cell Research & Therapy 2014, 5:134 Page 13 of 14
http://stemcellres.com/content/5/6/134studies related to the Ad-MSC biological properties and
their application as promising therapeutic tools in ex-
perimental medicine for autologous transplantations.
Other approaches are required to evaluate whether
these cells maintain a normal karyotype in the suggested
culture passages. Moreover, additional studies aimed to
establish a standard model for murine Ad-MSC expan-
sion and to unify the criteria of the scientific community
are warranted.
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